Standard Protocol Items News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Standard protocol items. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Standard Protocol Items Today - Breaking & Trending Today

"Study protocol for Care cOORDInatioN And sympTom managEment (COORDINAT" by Binu Koirala, Sarah Badawi et al.

INTRODUCTION: Sustainable approaches to support care coordination and symptom management needs of critically ill adults living with multimorbidity are needed to combat the challenges and complexity that multimorbidity presents. The study aims to test the feasibility of the Care cOORDInatioN And sympTom managEment (COORDINATE) intervention to improve health outcomes of adults living with multimorbidity. METHODS AND ANALYSIS: A multicomponent nurse-driven intervention was developed using experience-based co-design and human-centred design. Inclusion criteria include (1) age 55 years and older, (2) admitted to an intermediate care unit, (3) presence of two or more chronic health conditions and (4) signed informed consent. Data collection will occur at baseline (time of recruitment predischarge) and 6 weeks and 3 months following hospital discharge. Outcome of interest from this feasibility study is to evaluate the financial, technical and logistic feasibility of a full-scale study inclu ....

Standard Protocol Items , Interventional Trials , Institutional Review Board , Johns Hopkins Medical , Adult Intensive Critical Care , Quality In Health Care , Quality Of Life ,

Reporting of Factorial Randomized Trials

This article provides an extension of the Consolidated Standards of Reporting Trials 2010 checklist for the reporting of factorial trials. ....

City Of , United Kingdom , Brennanc Kahan , Clinical Trials Unit At University College London , Research Council , United Kingdom Office For National Statistics , United Kingdom National Institute For Health , National Institute Of Health Research , Better Research , Care Research , Transparency Of Health Research , Consolidated Standards , Reporting Trials , Health Research , Section Ref , Terms Used , Standard Protocol Items , Interventional Trials , Factorial Randomized Trials , Box Section Ref , Trials Unit , University College London , Drs Kahan , Interest Disclosures , United Kingdom Office , National Statistics ,

ICR experts develop clinical trial guidelines to support future research

ICR experts develop clinical trial guidelines to support future research
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Olga Solovyeva , Institute Of Cancer Research , Cancer Research , Statistics Unit , Standards Of Reporting Trials , Standard Protocol Items , Interventional Trials ,

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote gr ....

Glasgow City , United Kingdom , West Midlands , United Kingdom General , United States , Daiichi Sankyo , Janssen Clovis , Oxford Biotherapeutics , Lilly Incyte , Celgene Eisai , Sumitomo Dainippon Pharma , Genentech Roche , Bristol Myers Squibb , Astra Zeneca , Merck Serono , Sanofi Aventis , Cancer Research United Kingdom , International Delphi , United Kingdom Medical Research Council , United Kingdom Research , European Federation Of Pharmaceutical Industries , University Of Maastricht , University Of Birmingham , Takeda Pharmaceuticals , Imperial Biomedical Research Centre , Royal Marsden Institute Of Cancer Research ,

Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance

SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 provides guidance for clinical trial protocol writing. However, neither the original guidance nor its extensions adequately cover the features of early phase dose-finding trials. The SPIRIT Dose-finding Extension (DEFINE) statement is a new guideline that provides recommendations for essential items that should be provided in the protocols of these trials. It details extensions to the SPIRIT 2013 guidance, incorporating 17 new items and modifying 15 existing items. The purpose of this guideline is to promote transparency, completeness, reproducibility of methods, and interpretation of early phase dose-finding trial protocols. It is envisioned that the resulting improvements in the design and conduct of early phase clinical trials will ultimately reduce research inefficiencies and inconsistencies, driving transformational advances in clinical care.

Developing an intervention is a lengthy process purs ....

Glasgow City , United Kingdom , West Midlands , United Kingdom General , United States , Daiichi Sankyo , Oxford Biotherapeutics , Janssen Clovis , Lilly Incyte , Smith Kline , Celgene Eisai , Sumitomo Dainippon Pharma , Genentech Roche , Astra Zeneca , Merck Serono , Canadian Arthritis Patient Alliance , Outcomes Research Institute , Vertex Pharmaceuticals , Gilead Sciences , European Commission , Birmingham Health Partners Centre For Regulatory Science , Research Future Fund , United Kingdom Health Research Authority , Health Canada , Microbiology Research Centre , Bayer Ag ,